Loading...

LGND

LGN

LEGEND BIOTECH CORP

(LEGN)

2024 6-K

2025 Financial Results

10 Mar '26

Board Appointment

6 Feb '26

Board Changes

23 Jan '26

Sales Report

21 Jan '26

Corporate Update

14 Jan '26

Business Update Highlights

12 Jan '26

New Data Announcement

8 Dec '25

Financial Results Report

12 Nov '25

ASH Presentations

3 Nov '25

FDA Approval Update

14 Oct '25

Sales Announcement

14 Oct '25

Supply Agreement Update

7 Oct '25

Management Change

18 Aug '25

Financial Results Update

11 Aug '25

Sales Report

16 Jul '25

FDA Approval Update

30 Jun '25

Annual Meeting Results

12 Jun '25

Corporate Update

6 Jun '25

Leadership Appointment

5 Jun '25

CARVYKTI® Update

3 Jun '25

New Data Announced

22 May '25

New Headquarters Lease

14 May '25

Financial Update

13 May '25

Annual Meeting Notice

12 May '25

Sales Report

15 Apr '25

Q4 2024 Results

11 Mar '25

Sales Update

22 Jan '25

Corporate Presentation Update

14 Jan '25

Management Changes

23 Dec '24

Clinical Trial Results

9 Dec '24

Financial Update

12 Nov '24

MRD Data Announcement

5 Nov '24

Financial Deconsolidation

22 Oct '24

Annual Meeting Results

21 Oct '24

Sales Announcement

15 Oct '24

Survival Data Announcement

27 Sep '24

Annual Meeting Notice

20 Sep '24

Drug Approval News

27 Aug '24

Financial Results Update

9 Aug '24

Board Appointment

8 Aug '24

Preliminary Financial Results

26 Jul '24

Sales Announcement

17 Jul '24

Positive Trial Results

2 Jul '24

CARVYKTI Update

3 Jun '24

CAR-T Presentation Update

23 May '24

Financial Results Q1 2024

13 May '24

EU Approval Granted

22 Apr '24

Sales Announcement

16 Apr '24

FDA Approval Granted

8 Apr '24

Manufacturing Agreement

29 Mar '24

FDA Recommendation

15 Mar '24

FDA Briefing Release

13 Mar '24

Earnings Update

11 Mar '24

Positive CHMP Opinion

23 Feb '24

FDA Update Announcement

23 Jan '24

Sales Announcement

23 Jan '24

Corporate Update

9 Jan '24

External Links:

SEC

On July 2, 2024, Legend Biotech announced positive overall survival results from its CARTITUDE-4 Phase 3 trial for CARVYKTI® in treating multiple myeloma patients, showing significant improvement over traditional treatments. This is considered a significant event for the company.

AI Assistant

LEGEND BIOTECH CORP

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.